Giorgio V.
- Country
- Italy
- Department
- Oncology
Research Overview
- A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- Phase 2 Study of ACR-368 and Gemcitabine in Subjects with Endometrial Cancer
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
Data & Insights
Has run more than one trial at 293 of 584 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating various gynecologic malignancies, with particular focus on advanced therapeutic approaches for ovarian cancer, endometrial cancer, and cervical cancer.
- BRCA wild-type ovarian cancer management
- Advanced peritoneal and fallopian tube cancers
- Recurrent endometrial carcinoma treatment
- Locally advanced cervical cancer therapies
Targeted Therapies
The investigator works with innovative targeted therapeutic approaches across multiple cancer types, including hormone receptor-positive breast cancer and specialized treatments for gastrointestinal malignancies.
- FGFR2b-targeted treatments
- ER+/HER2- breast cancer therapy
- Advanced gastric cancer treatment
- Immunotherapy combinations
Urologic Oncology
The investigator focuses on treating various stages of bladder cancer, including both non-muscle invasive and muscle-invasive disease states.
- High-risk non-muscle invasive bladder cancer
- BCG-unresponsive disease management
- Neoadjuvant treatment approaches
- Novel immunotherapy combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.